Navigation Links
Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
Date:6/2/2009

CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today that the FDA's Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee voted that Restanza did not demonstrate efficacy in the treatment of CAP (3 positive, 11 negative, 1 abstaining).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

"We believe in Restanza's potential and remain committed to its development. We were particularly encouraged by the supportive comments of several members of the committee relative to their positive review of the safety profile of Restanza, the therapeutic need for more effective treatments for CAP and their interest in seeing the company pursue further development," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "As we have throughout the review process we will continue to work closely with the FDA as they complete their assessment of the Restanza new drug application (NDA)."

Although it is not binding, the Committee's recommendation will be considered by the FDA as it completes its review of Restanza's NDA in CAP. The FDA has established a Prescription Drugs User Fee Act (PDUFA) date of July 31, 2009 for the Restanza NDA.

Conference Call Details

Advanced Life Sciences will host a conference call and live webcast at 8:30 a.m. Eastern Time on Wednesday, June 3, 2009 to discuss the outcome of the AIDAC Review.

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website '/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
11. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...CHICAGO and STAFA, Switzerland, Nov. 25 /PRNewswir...nufacturer of innovative hearing solutions, presen...lts Conference, focusing on the special needs of t...er leading experts in aging and audiology from aro...k everyday with older people with hearing loss for...
(Date:11/25/2009)..., COLLEGE PARK, Md., Nov. 25 /PRNewswire-USNewswir...ping a shaving cream-like foam that stops severe b...romising Security Idea category of the Global Secu...day. ,, Selected from more than 100 entries fro...invention at the GSC Security Summit conference he...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportlink... is available in its catalogue: ,, United Stat... 2015 ,, http://www.reportlinker.com/p0158733...Forecasts-to-2015.html ,, United States Dental..., Summary ,, This report is an essential sou...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13IBM and EU Partners Create a Better Way to Fight AIDS Virus 4525 1IBM and EU Partners Create a Better Way to Fight AIDS Virus 4525 2IBM and EU Partners Create a Better Way to Fight AIDS Virus 4525 3IBM and EU Partners Create a Better Way to Fight AIDS Virus 4525 4Vision impairment costs billions lost in productivity 47719 1Vision impairment costs billions lost in productivity 47719 2Pelosi Remarks Before Meeting with Secretary of Health and Human Services Kathleen Sebelius 47718 1Pelosi Remarks Before Meeting with Secretary of Health and Human Services Kathleen Sebelius 47718 2
... in a Poster Session at the 67th Annual Meeting of...ANCISCO, March 6 Galderma Laboratories, L.P. toda...ntial treatment of plaque psoriasis using Clobex (...y treatment with Vectical(TM) (calcitriol) Ointmen...he data are to be presented in a poster session at...
...mboGenics NV,(Euronext Brussels: THR), a biotechno...eye disease, vascular disease and cancer, today an...r a Phase II trial of microplasmin,intravitreal in...a (MIVI II,DME). This trial is designed as the ini...n in patients with diabetes, a group which is more...
Other Medicine Technology:Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 2Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 3Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 4ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3
(Date:11/27/2009)...e anatomy education apps from Modality and Lippinc...learning opportunities for iPhone and iPod touch ...ber 27, 2009 -- Modality, Inc. and Lippincott Wi...Kluwer Health, today announced the availability of.... Clemente’s Anatomy, Rohen’s Photogra...
(Date:11/26/2009)...wire/ -- The diabetes population in the United Sta...annual medical spending on the disease is projecte... according to a study published in the December is...abetes ® Program (NCDP), a program of Novo No...e University of Chicago. ,, According to the fo...
(Date:11/26/2009)...ate (TM) has been shown in studies to be effective...sed by an overload of copper, and certain metastat...er, is known about how the drug works at the molec...iversity researchers now has provided an invaluabl...d to copper-loaded metallochaperones. The drug seq...
(Date:11/26/2009)...rollercoaster, study finds , , THURSDAY,...or meets the jubilant sports fan. , A new study...root for the winning team -- enjoy the greatest sa...ictory was in doubt, producing feelings of worry a...ng weekend as you,re glued to the TV set, watching...
(Date:11/26/2009)... Live Life Again Center, a practice offering weig...mber of physicians who are taking advantage of po...viduals who are interested in surgical weight loss...lizing Facebook to share before-and-after photos a...ty. , Dallas, TX (Vocus) ...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3
...Techniques Act is to be enforced strictly in Keral... P K Sreemathi said today. // Addressing rep...as the sex ratio in the state, which was healthy a...d the previous government did not do anything to c...
...ent A P J Abdul Kalam today met representatives of...break the impasse with the students and doctors de...-member delegation of agitating medicos, which als...d a charter of demands to Kalam. We respect P...
...s on the NHS worsened today after Oxford Radcliffe...at only fit into its budget.// The Trust operates ...d that compulsory job losses cannot be ruled out a...mber could only double by the end of the year. ...
... and Haryana were paralysed today as doctors of bo...he OPDs in the wake of a 'medical bandh' called by...tre's reservation proposal. "All OPDs, includ...(ARD) Vice President Dr. Anindya Banerjee said her...
...hip was announced by the greater Southern Area Hea...he family who are unable to support// patients aff...e which provides region’s new family sensitive men...ntal health, said that it was good news for famili...
... director-general Dr. Lee Jong-wook dies on 23rd o...lood clot in his brain//. He was undergoing an eme...ng-wook who is 61 years old suffered from discomfo...tor-general in 2003. During his tenure he attempte...
Other Medicine News:Health News:President Kalam Meets Striking Medicos However Stir to Continue 2
FLEXILOG 2000 Pouch and Belt
13848 Buffer Solution pH 4.00 (250ml)
FLEXILOG Trolley for Stationary System
Bravo Vacuum Pump
Medicine Products: